Brittney Mize, PhD
Research & Expertise:
Biography
Brittney Mize, PhD, earned a Bachelor of Science in Biochemistry and Molecular Biology from Otterbein University in 2018 and obtained her Adolescent to Young Adult (AYA) Life Science Ohio Teaching License in 2021. She completed her PhD in Pharmaceutical Sciences at The Ohio State University in 2023 under the mentorship of Dr. James Fuchs. Her dissertation research focused on developing analogs of natural products with anti-ovarian cancer activity, identifying their molecular targets, and designing novel CDK9 degraders.
Dr. Mize was awarded The Ohio State University Presidential Fellowship in 2018 and has presented her research at numerous local and national conferences. In addition to her work in medicinal chemistry, she earned an Inclusive Teaching Endorsement from The Ohio State Drake Institute in 2022 and taught Organic Chemistry at Otterbein University from 2023 to 2024.
Dr. Mize's current work centers on advancing chemical literacy and supporting student success among undergraduate and Doctor of Pharmacy (PharmD) learners in the College of Pharmacy.
Education
- 2023 - Doctor of Philosophy, Pharmaceutical Science, The Ohio State University College of Pharmacy
- 2021 - Master of Science, Pharmaceutical Science, The Ohio State University College of Pharmacy
- 2018 - Bachelor of Science, Biochemistry/Molecular Biology, Otterbein University
Honors
- 2025 - College of Pharmacy 2025 Inspire Teaching Awards for Instructional Excellence
- 2020 - Medicinal Chemistry Service Award
- 2018 - OSU University Fellowship
Publications
- Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation, European Journal of Medicinal Chemistry. 2023 Jun | journal-article. doi: 10.1016/j.ejmech.2023.115342.
- Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer, Natural Product Reports. 2023 Jan | journal-article. doi: 10.1039/D2NP00091A.
- Discovery of Anticancer Agents of Diverse Natural Origin, Journal of Natural Products. 2022 Mar | journal-article. doi: 10.1021/acs.jnatprod.2c00036.
- PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer, Cell Death & Disease. 2022 Jan | journal-article. doi: 10.1038/s41419-021-04495-w.